Pathogenesis of lesions in late age-related macular disease;Pathogénie des lésions de la dégéné rescence maculaire liée à l'âge à un stade avancé

Journal Francais d'Ophtalmologie

Volumn 28, Issue 9, 2005, Pages 984-990

  Bird, A C ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

Age related macular degeneration; Choroidal neovascularization; Geographic atrophy; Pathogenesis; Pigment epithelial detachment

Indexed keywords

GROWTH FACTOR; VISUAL PIGMENT;

ATROPHY; AUTOFLUORESCENCE; BRUCH MEMBRANE; CELL MEMBRANE; CELL PROLIFERATION; LIPID STORAGE; PATHOGENESIS; PIGMENT EPITHELIUM; PROTEIN DOMAIN; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SUBRETINAL NEOVASCULARIZATION; VISUAL IMPAIRMENT; WATER FLOW;

EID: 29444459113     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0181-5512(05)81128-3     Document Type: Article

References (47)

1. Gass JD. Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol, 1967;63(Suppl):1-139.
2. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials. Arch Ophthalmol, 1986;104:503-12.
3. Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Arch Ophthalmol, 1994;112:500-9.
4. Bressler NM. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials. Arch Ophthalmol, 2001;119:198-207.
5. Submacular Surgery Study Group. Submacular surgery trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration: I. Ophthalmic outcomes submacular surgery trials pilot study report number 1. Am J Ophthalmol, 2000;130:387-407.
6. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res, 2003;22:1-29.
7. Yamagishi K, Ohkuma H, Itagaki T, Katoh N, Takahashi K, Uyama M. Implication of retinal pigment epithelium on experimental subretinal neovascularization in the developmental stage. Nippon Ganka Gakkai Zasshi, 1988;92:1629-36.
8. Hangai M, Murata T, Miyawaki N, Spee C, Lim JI, He S, et al. Angiopoietin-1 upregulation by vascular endothelial growth factor in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci, 2001;42:1617-25.
9. Kamizuru H, Kimura H, Yasukawa T, Tabata Y, Honda Y, Ogura Y. Monoclonal antibody-mediated drug targeting to choroidal neovascularization in the rat. Invest Ophthalmol Vis Sci, 2001;42:2664-72.
10. Yasukawa T, Kimura H, Tabata Y, Miyamoto H, Honda Y, Ikada Y, et al. Active drug targeting with immunoconjugates to choroidal neovascularization. Curr Eye Res, 2000;21:952-61.
11. Moore DJ, Hussain AA, Marshall J. Age-related variation in the hydraulic conductivity of Bruch's membrane. Invest Ophthalmol Vis Sci, 1995;36:1290-7.
12. Yannuzzi LA, Negrao S, Iida T, Carvalho C, Rodriguez-Coleman H, Slakter J, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina, 2001;21:416-34.
13. Saishin Y, Saishin Y, Takahashi K, Lima e Silva R, Hylton D, Rudge JS, et al. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol, 2003;195:241-8.
14. Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol, 2002;120:338-46.
15. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology, 2003;110:979-86.
16. The Eyetech Study Group. Preclinical and phase IA clinical evaluation of an anti-VEGF pegylated aptamer (EYE 001) for the treatment of exudative age-related macular degeneration. Retina, 2002;22:143-52.
17. Renno RZ, Youssri AI, Michaud N, Gragoudas ES, Miller JW. Expression of pigment epithelium-derived factor in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci, 2002;43:1574-80.
18. Rasmussen H, Chu KW, Campochiaro P, Gehlbach PL, Haller JA, Handa JT, et al. Clinical Protocol, An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther, 2001;12:2029-32.
19. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science, 1985;230:1375-8.
20. McNatt LG, Weimer L, Yanni J, Clark AF. Angiostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization. J Ocul Pharmacol Ther, 1999;15:413-23.
21. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger S, Luna S, et al. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. Retina, 2003;23:14-23.
22. Bird AC, Marshall J. Retinal pigment epithelial detachments in the elderly. Trans Ophthalmol Soc UK, 1986;105:674-82.
23. Green WR, Key SN. Senile macular degeneration: a histopathological study. Tr Am Ophthalmol Soc, 1977;75:180-250.
24. Ramrattan RS, Van der Schaft TL, Mooy CM, De Bruijn WC, Mulder PG, De Jong PT. Morphometric analysis of Bruch's membrane, the choriocapillaris, and the choroid in aging. Invest Ophthalmol Vis Sci, 1994;35:2857-64.
25. Okubo A, Rosa RH, Bunce KV, Alexander RA, Fan JT, Bird AC, et al. The relationships between age changes in retinal pigment epithelium and Bruch's membrane. Invest Ophthalmol Vis Sci, 1999;40:443-9.
26. Pauleikhoff D, Harper CA, Marshall J, Bird AC. Aging changes in Bruch's membrane: a histochemical and morphological study. Ophthalmology, 1990;97:171-8.
27. Sheraidah G, Steinmetz R, Maguire J, Pauleikhoff D, Marshall J, Bird A. Correlation between lipids extracted from Bruch's membrane and age. Ophthalmology, 1993;100:47-51.
28. Moore DJ, Hussain AA, Marshall J. Age related variation in the hydraulic conductivity of Bruch's membrane. Invest Ophthalmol Vis Sci, 1995;36:1290-7.
29. Starita C, Hussain AA, Patmore A, Marshall J. Localization of the site of major resistance to fluid transport in Bruch's membrane. Invest Ophthalmol Vis Sci, 1997;38:762-7.
30. Pauleikhoff D, Zuels S, Sheraidah G, Marshall J, Wessing A, Bird AC. Correlation between biochemical composition and fluorescein binding of deposits in Bruch's membrane. Ophthalmology, 1992;99:1548-53.
31. Chuang EL, Bird AC. Bilaterality of tears of the retinal pigment epithelium. Br J Ophthalmol, 1988;72:918-20.
32. Chuang EL, Bird AC. The pathogenesis of tears of the retinal pigment epithelium. Am J Ophthalmol, 1988;105:185-90.
33. Pauleikhoff D, Loffert D, Spital G, Radermacher M, Dohrmann J, Lommatzsch A, et al. Pigment epithelial detachment in the elderly. Clinical differentiation, natural course and pathogenetic implications. Graefes Arch Clin Exp Ophthalmol, 2002;240:533-8.
34. Holz FG, Bellman C, Staudt S, Schutt F, Volcker HE. Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci, 2001;42:1051-6.
35. Lois N, Holder GE, Bunce C, Fitzke FW, Bird AC. Phenotypic subtypes of Stargardt macular dystrophy-fundus flavimaculatus. Arch Ophthalmol, 2001;119:359-69.
36. Curcio CA, Medeiros NE, Millican CL. Photoreceptor loss in age-related macular degeneration. Invest Ophthalmol Vis Sci, 1996;37:1236-49.
37. Katz ML, Norberg M. Influence of dietary vitamin A on autofluorescence of leupeptin-induced inclusions in the retinal pigment epithelium. Exp Eye Res, 1992;54:239-46.
38. Von Rückmann A, Fitzke FW, Bird AC. Distribution of fundus autofluorescence with a scanning laser ophthalmoscope. Br J Ophthalmol, 1995;79:407-12.
39. Delori FC, Dorey CK, Staurenghi G, Arend O, Goger DG, Weiter JJ. In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelial lipofuscin characteristics. Invest Ophthalmol Vis Sci, 1995;36:718-29.
40. Lois N, Coco R, Hopkins J, Owens SL, Fitzke FW, Bird AC. Fundus autofluorescence in patients with age-related macular degeneration and high risk characteristics. Am J Ophthalmol, 2002;133:341-9.
41. Rozanowska M, Korytowski W, Rozanowski B, Skumatz C, Boulton ME, Burke JM, et al. Photoreactivity of aged human RPE melanosomes: a comparison with lipofuscin. Invest Ophthalmol Vis Sci, 2002;43:2088-96.
42. Holz FG, Schutt F, Kopitz J, Eldred GE, Kruse FE, Volcker HE, et al. Inhibition of lysosomal degradative functions in RPE cells by a retinoid component of lipofuscin. Invest Ophthalmol Vis Sci, 1999;40:737-43.
43. Schutt F, Bergmann M, Holz FG, Kopitz J. Isolation of intact lysosomes from human RPE cells and effects of A2-E on the integrity of the lysosomal and other cellular membranes. Graefes Arch Clin Exp Ophthalmol, 2002;240:983-8.
44. Okubo A, Sameshima M, Unoki K, Uehara F, Bird AC. Ultrastructural changes associated with accumulation of inclusion bodies in rat retinal pigment epithelium. Invest Ophthalmol Vis Sci, 2000;41:4305-12.
45. Wiegand RD, Koutz CA, Stinson AM, Anderson RE. Conservation of docosahexaenoic acid in rod outer segments of rat retina during n-3 and n-6 fatty acid deficiency. J Neurochem, 1991;57:1690-9.
46. Stinson AM, Wiegand RD, Anderson RE. Recycling of docosahexaenoic acid in rat retinas during n-3 fatty acid deficiency. J Lipid Res, 1991;32:2009-17.
47. Radu RA, Mata NL, Nusinowitz S, Liu X, Sieving PA, Travis GH. Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration. Proc Natl Acad Sci USA, 2003;100:4742-7.